Sickle cell anemia disease with crisis. Hb-SS disease with crisis
Conditions
Interventions
Intervention group:.
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Patients who have been hospitalized more than three times a year and for more than 4 hours each time due to pain crises. Their pain crisis was not controlled by receiving 15 milligrams per kilogram of hydroxyurea every 12 hours.
Exclusion criteria
Exclusion criteria: Patients should not be treated with other anticancer drugs. CYP3A4 inducers such as rifampin, rifabutin, carbamazepine, and phenobarbital should not be taken the day before or during imatinib administration. CYP3A4 inhibitors such as azole antifungals (itraconazole and ketoconazole), clarithromycin, erythromycin, diltiazem, verapamil, HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfainavir), and delavirdine should not be taken within 7 days of receiving imatinib. Patients also must not have uncontrolled infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of pain-related hospitalizations per year in patients with hydroxyurea-resistant sickle cell disease. Timepoint: Every three months. Method of measurement: The number of hospitalizations per patient due to pain crises over one year will be recorded from medical records and hospital documentation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of hematological and biochemical parameters. Timepoint: every three months. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactladan mafakher
Ahvaz University of Medical Sciences
Outcome results
None listed